Alzheimer's Disease Clinical Trials in Maitland, Florida

5 studies are recruiting for alzheimer's disease in Maitland, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

   This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.

   Stage

   Phase 3

   Ages

   55 to 80

   Site

   K2 Medical Research, LLC, Maitland, Florida

   Locations

   7 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT07717411 on ClinicalTrials.gov

2. An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

   VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study

   Stage

   Phase 1

   Ages

   30 to 80

   Site

   K2 Medical Research, LLC, Maitland, Florida

   Run by

   Voyager Therapeutics

   See if you can join NCT07764146 on ClinicalTrials.gov

3. A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

   This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.

   Stage

   Phase 2

   Ages

   50 to 85

   Site

   K2 Medical Research LLC, Maitland, Florida

   Locations

   74 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT07094516 on ClinicalTrials.gov

4. Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

   Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful rel…

   Stage

   Not phased

   Ages

   60 to 90

   Site

   K2 Medical Research, Maitland, Florida

   Locations

   26 in total

   Run by

   GAP Innovations, PBC

   See if you can join NCT06584357 on ClinicalTrials.gov

5. Open-label Extension Study in Participants With Early Alzheimer's Disease

   The study medicine GSK4527226 is being studied in participants with Alzheimer's Disease (AD) in study 219867 (the parent study, NCT06079190). This new study is an extension of that parent study called an open-label extension (OLE). An OLE is a clinical trial where all participants receive the same …

   Stage

   Phase 2

   Ages

   50 to 85

   Site

   GSK Investigational Site, Maitland, Florida

   Locations

   33 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT07105709 on ClinicalTrials.gov